MedTrace Logo

MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients

NCT01264874 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-01-31

No results posted yet for this study

Summary

The purpose of this trial is to assess the effect of vitamin D supplementation on recurrence in resected stage II melanoma patients.

Conditions

Interventions

DRUG

Vitamin D3 ( Colecalciferol)

100000 IU every 50 days for 3 years

OTHER

placebo

For 3 years IU every 50 days

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Alessandro Testori, MD · European Institute of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01264874 on ClinicalTrials.gov